COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00073840
Recruitment Status : Completed
First Posted : December 11, 2003
Last Update Posted : February 22, 2012
Information provided by (Responsible Party):

Brief Summary:
The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Condition or disease Intervention/treatment Phase
Asthma Drug: levalbuterol Phase 3

Detailed Description:
A double-blind, randomized, placebo- and active-controlled, multicenter, parallel-group trial of levalbuterol in subjects 12 years of age and older with asthma. Study participation will include one 1-week single-blind placebo run-in and an 8-week, randomized,double-blind, active-treatment period with four treatment groups. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 386 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
Study Start Date : December 2002
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: I
Levalbuterol 90 ųg QID (manufacturing site A or B)
Drug: levalbuterol
  • Levalbuterol 90 ųg QID (manufacturing sites A or B);
  • Racemic Albuterol 180 ųg QID;
  • Placebo QID
Other Name: Xopenex HFA (levalbuterol tartrate)Inhalation Aerosol

Active Comparator: II
Racemic Albuterol 180 ųg QID
Drug: levalbuterol
  • Levalbuterol 90 ųg QID (manufacturing sites A or B);
  • Racemic Albuterol 180 ųg QID;
  • Placebo QID
Other Name: Xopenex HFA (levalbuterol tartrate)Inhalation Aerosol

Placebo Comparator: III
Placebo QID
Drug: levalbuterol
  • Levalbuterol 90 ųg QID (manufacturing sites A or B);
  • Racemic Albuterol 180 ųg QID;
  • Placebo QID
Other Name: Xopenex HFA (levalbuterol tartrate)Inhalation Aerosol

Primary Outcome Measures :
  1. FEV1 (peak percent change from pre-dose averaged over the double-blind period). [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. --FEV1 [area under the % change from pre-dose FEV1 curve] and FEV1 [area under the % change from study baseline FEV1 curve] [ Time Frame: 9 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Must give written informed consent (IC) prior to participation in the study. For subjects 12 - 17 years of age, the IC must be signed parent or legal guardian. Females must sign the Women of Childbearing Potential Addendum
  • Be willing and able to comply with the study procedures and visit schedules
  • Male or female, at least 12 years of age
  • Females 12-60 years of age must have a negative serum pregnancy test at Visit 1 (V1)
  • Women of child bearing potential must be using an acceptable method of birth control
  • Must have a documented diagnosis of asthma for a min. of 6 mos. prior to V1
  • At V1, the subject must demonstrate a baseline FEV1 within >45% and <75% of predicted for their height, age, gender, and race
  • Following abstention from medications used to treat asthma, subject must demonstrate >12% reversibility of airflow obstruction within 15-30 min. following inhalation of 180 µg (2 actuations, 90 µg ea.) of racemic albuterol MDI
  • Must have stable baseline asthma and have been using a B-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or OTC asthma medication for at least 6 mos. prior to V1
  • Must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function
  • Must have a chest X-ray that is not diagnostic of pneumonia, atelectasis, pulmonary fibrotic disease, pneumothorax, chronic obstructive pulmonary disease, etc.
  • Must be able to complete the diary cards and medical event calendars reliably on a daily basis and demonstrate how to use the MiniWright PEF meter

Exclusion Criteria

  • Subject who is expected to require any disallowed medications
  • Female subject who is pregnant or lactating
  • Subject who has participated in an investigational drug study within 30 days prior to V1, or who is currently participating in another clinical trial
  • Schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 9AM
  • Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both
  • Subject who has a history of hospitalization for asthma within 45 days prior to V1, or who is scheduled for in-patient hospitalization during the trial
  • Have a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations
  • Subject using any prescription drug with which albuterol sulfate administration is contraindicated
  • Subject with currently diagnosed life-threatening asthma
  • Subject with clinically significant abnormalities that may interfere with the metabolism or excretion of the study drug
  • Have a history of cancer (exception: basal cell carcinoma in remission)
  • Have hyperthyroidism, diabetes, hypertension, cardiac diseases, or seizure disorders not well controlled by medication or that may interfere with the successful completion of this protocol
  • Have a history of substance or drug abuse within 12 mos. preceding V1 or a positive urine drug screening at V1
  • Have greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 mos. of V1
  • Have a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis
  • Have suffered from a clinically significant upper or lower respiratory tract infection in the 2 weeks prior to V1
  • Have any clinically significant abnormal laboratory values
  • Have a clinically significant abnormal 12-lead ECG that may jeopardize the subject's ability to complete study
  • Subject who is a staff member or relative of a staff member

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00073840

Show Show 54 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Chair: John Hanrahan, M.D. Sunovion
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sunovion Identifier: NCT00073840    
Other Study ID Numbers: 051-355
First Posted: December 11, 2003    Key Record Dates
Last Update Posted: February 22, 2012
Last Verified: February 2012
Keywords provided by Sunovion:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action